BMS Exercises its Option to Develop Exscientia's AI-Designed Drug Candidate
Shots:
- Exscientia to receive $20M as an option exercise fee and is eligible for development milestones along with royalties on any product sales
- BMS has elected to in-license an Exscientia’s immune-modulating drug candidate & will be responsible for clinical and commercial development of the product
- In May’21- the companies have expanded the collaboration to accelerate the discovery of drug candidates by using Exscientia’s AI technology for multiple therapeutic areas- including oncology and immunology
Ref: Exscientia | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com